Live | Norge | Sverige | Danmark | Europa | USA | Valuta | Råvarer | Gråmarked | Fond | NDXForsinkede kurser. Sist oppdatert: fredag 22. juni
Teknisk analyse
Nyheter
Om BGBIO
Intradagsgraf
Korrelasjoner
Handelslogg
Dybdelogg
Dataeksport
Legg til interesseliste
Handle BGBIO
Sanntidssnapshot
Dato Antall dager Distributør Papir Børs Søk  
Dato Tid Selskap Overskrift
18/06-2018 09:46:01 BGBIO BerGenBio: Posters presented at Congress of European Hematology Association (EHA) (OBI)
04/06-2018 16:30:00 BGBIO SBX Doblingskandidat til værs på børsen (Hegnar)
  07:54:00 BGBIO Fersk oppdatering fra biotekselskap (Hegnar)
03/06-2018 16:45:21 BGBIO BerGenBio provides interim update on Phase II clinical programme with selective oral AXL inhibitor bemcentinib (OBI)
  16:45:00 BGBIO BerGenBio provides interim update on Phase II clinical programme with selective oral AXL inhibitor bemcentinib (Cision)
02/06-2018 14:55:32 BGBIO BerGenBio ASA US CLINICAL TRIAL UPDATE (OBI)
01/06-2018 14:10:00 MPCC SBO BGBIO Kliner til med tre nye rekordnoteringer på børsen (Hegnar)
29/05-2018 08:00:11 BGBIO BerGenBio - Invitation to conference call: interim update on Ph II clinical programme with selective AXL inhibitor bemcentinib being presented at ASCO (OBI)
  08:00:00 BGBIO BerGenBio - Invitation to conference call: interim update on Ph II clinical programme with selective AXL inhibitor bemcentinib being presented at ASCO (Cision)
23/05-2018 17:10:00 BGBIO Opsjonsdryss i BerGenBio (Hegnar)
  17:03:55 BGBIO BerGenBio ASA: Share options to primary insiders (OBI)
18/05-2018 10:00:17 BGBIO BerGenBio to present interim clinical and biomarker data with selective AXL inhibitor bemcentinib in AML and MDS at EHA (OBI)
  10:00:00 BGBIO BerGenBio to present interim clinical and biomarker data with selective AXL inhibitor bemcentinib in AML and MDS at EHA (Cision)
16/05-2018 23:00:14 BGBIO BerGenBio to present interim clinical and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO (OBI)
  23:00:00 BGBIO BerGenBio to present interim clinical and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO (Cision)
15/05-2018 07:06:00 BGBIO BerGenBio: 1. kvartal (Hegnar)
  07:00:16 BGBIO BerGenBio ASA: Results for the First Quarter 2018 (OBI)
  07:00:00 BGBIO BerGenBio ASA: Results for the First Quarter 2018 (Cision)
14/05-2018 12:30:21 BGBIO BerGenBio participation at upcoming healthcare investor and life sciences industry conferences (OBI)
  12:30:00 BGBIO BerGenBio participation at upcoming healthcare investor and life sciences industry conferences (Cision)
  12:25:17 BGBIO BerGenBio ASA: Annual General Meeting (OBI)
  08:58:00 PLCS BGBIO - Kjøp disse aksjene (Hegnar)
08/05-2018 16:01:19 BGBIO BerGenBio ASA: Invitation to First Quarter 2018 Results Presentation and Webcast (OBI)
  16:01:00 BGBIO BerGenBio ASA: Invitation to First Quarter 2018 Results Presentation and Webcast (Cision)
23/04-2018 15:44:49 BGBIO BerGenBio ASA (BGBIO): Notice of annual general meeting (OBI)
  15:35:48 BGBIO BerGenBio ASA (OSE:BGBIO): Annual report 2017 (OBI)
19/04-2018 14:26:00 BGBIO RIVER-ME Du kunne doblet pengene dine på 27 dager (Hegnar)
  09:39:55 BGBIO BerGenBio ASA: Share capital increase (OBI)
18/04-2018 08:08:00 BGBIO BerGenBio: - Lovende data (Hegnar)
  08:00:11 BGBIO BerGenBio: Lovende data som viser selektiv AXL inhibitor bemcentinibs potensiale til å forbedre effekten av sjekkpunkthemmere ble presentert på AACR (OBI)
  08:00:11 BGBIO BerGenBio: Promising data highlighting selective AXL inhibitor bemcentinib's potential to improve efficacy of checkpoint inhibitors presented at AACR (OBI)
  08:00:00 BGBIO BerGenBio: Lovende data som viser selektiv AXL inhibitor bemcentinibs potensiale til å forbedre effekten av sjekkpunkthemmere ble presentert på AACR (Cision)
  08:00:00 BGBIO BerGenBio: Promising data highlighting selective AXL inhibitor bemcentinib's potential to improve efficacy of checkpoint inhibitors presented at AACR (Cision)
13/04-2018 13:48:07 BGBIO BerGenBio ASA: Share capital increase (OBI)
  08:42:00 BGBIO Gladmelding fra BerGenBio (Hegnar)
  08:00:17 BGBIO Promising pre-clinical data supporting BerGenBio's pipeline to be published and presented at upcoming leading conferences (OBI)
  08:00:00 BGBIO Promising pre-clinical data supporting BerGenBio's pipeline to be published and presented at upcoming leading conferences (Cision)
  07:39:00 BGBIO Overtegnet emisjon for BerGenBio (Hegnar)
  07:15:25 BGBIO BerGenBio ASA announces successful NOK 187.5 million (USD 24 million) private placement of new shares (OBI)
  07:15:00 BGBIO BerGenBio ASA announces successful NOK 187.5 million (USD 24 million) private placement of new shares (Cision)
10/04-2018 08:52:00 BGBIO BerGenbio i mål med pasientrekruttering (Hegnar)
  08:00:19 BGBIO BerGenBio completes recruitment into first stage of Phase II NSCLC trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA (OBI)
  08:00:00 BGBIO BerGenBio completes recruitment into first stage of Phase II NSCLC trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA® (Cision)
05/04-2018 17:54:14 BGBIO BerGenBio ASA: Board approval of 2017 annual financial statement (OBI)
  17:43:58 BGBIO BerGenBio ASA: Exercise of employee share options and increase of capital (OBI)
22/03-2018 13:55:00 BGBIO Selv etter de siste ukenes kursfall kunne du doblet pengene (Hegnar)
  08:00:23 BGBIO BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe (OBI)
  08:00:00 BGBIO BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe (Cision)
20/03-2018 13:35:59 BGBIO BerGenBio ASA: Share capital increase (OBI)
15/03-2018 08:33:00 BGBIO BerGenBio presenterer «lovende data» (Hegnar)
Sidestørrelse:
Utforming |  Hjelp |  Utskrift  | Bytt til sanntid  Åpne markeder: Nasdaq, Nyse, Amex
fredag 22/06-2018 21:08:52